Polynucleotide-based hair-loss treatment is an emerging, generally well-tolerated option being studied for androgenetic alopecia. Early clinical studies report possible improvements in hair density or thickness, but the evidence remains limited, protocols are not standardized, and treatment should not yet be presented as an established alternative to approved therapies.
Androgenetic alopecia, also called male or female pattern hair loss, is a common nonscarring condition characterized by progressive follicular miniaturization after puberty [1]. Prevalence varies according to age, sex, ethnicity, and study population; it affects approximately 80% of men and nearly 50% of women by age 70 in some populations. Medical treatments such as topical minoxidil and, for appropriate men, oral finasteride are established options, while hair transplantation may be considered for selected patients.
But advancements in regenerative medicine have expanded the spectrum of available treatments for alopecia. In this article, let’s understand all about polynucleotides for hair loss treatment.
Key Takeaways
- Polynucleotides for hair improve blood supply to hair follicles, reduce inflammation, help in tissue repair, and promote moderate hair regrowth.
- The recommended injection techniques for polynucleotides are microneedling and the linear retrograde method using 30–32 gauge needles.
- Polynucleotides work well with other therapies such as platelet-rich plasma therapy, microneedling, and topical treatments.
- The procedure is safe with few side effects.
- Results can last between 6 to 12 months, and noticeable hair improvements start within six weeks.
How Do Polynucleotides Stop Hair Loss?
Polynucleotide-based hair treatments are injectable preparations containing purified DNA-derived polymers. Some products use longer-chain polynucleotides, while related PDRN products contain shorter DNA fragments. Their source, composition, concentration, and regulatory status vary by product.
PN and PDRN have been studied in regenerative medicine for possible effects on inflammation, tissue repair, cellular signaling, and dermal remodeling. These proposed mechanisms do not, by themselves, establish clinical hair regrowth.
Furthermore, PN and PDRN are proposed to influence angiogenesis-related signaling, inflammation, oxidative stress, and the follicular microenvironment. However, they have not been shown to stop androgenetic alopecia, and the clinical relevance of these mechanisms for hair regrowth remains uncertain.
Laboratory and early translational research suggests that some PN or PDRN preparations may affect dermal papilla cells and growth-factor pathways, including VEGF-related signaling. These findings provide biological plausibility but do not prove that injectable PN reliably reverses follicular miniaturization in patients.
Do Polynucleotides Work for Hair Growth?
In a 2024 study of a polynucleotide-based gel for pattern hair loss, investigators reported improvement ratings at follow-up assessments over approximately 24 weeks [2]. Because the study evaluated a specific product and its design and outcome measures limit generalization, the findings should be interpreted as preliminary rather than proof that PN produces reliable hair regrowth in all patients.
A 2021 expert-consensus report described PN-HPT™ as a potential option for scalp skin quality and hair-thickening protocols. Because this was a consensus document rather than a randomized controlled trial, its recommendations should be presented as expert guidance, not definitive evidence of efficacy.
The consensus report described a multi-session PN-HPT™ protocol, but treatment volume, concentration, injection interval, and maintenance schedule should not be treated as universal [3]. Providers must follow the current product documentation, local regulations, and their clinical training.
PN-based treatment may be combined with topical or procedural therapies in selected patients, but evidence that these combinations amplify hair growth is limited. Biotin is unlikely to help unless a deficiency is present, and the use of supplements or additional procedures should be based on a medical assessment.
Who Should Get Polynucleotides for Hair Injections?
Polynucleotides for hair restoration injections are indicated for:
- Patients with scalp conditions involving follicular miniaturization, alopecia, and hair thinning, particularly those with androgenetic alopecia classified as Norwood 3–6 on the standard scale or telogen effluvium
- Those receiving adjunctive treatments like PRP or low-level laser therapy (LLLT)
- Patients who have not seen satisfactory results from pharmacological agents like minoxidil and finasteride
- Patients undergoing hair transplant surgery to support post-surgical follicle recovery
Injection Techniques and Procedural Considerations
Treatment should be individualized according to the diagnosis, scalp anatomy, product instructions, and clinical training. No injection technique guarantees hair regrowth or prevents dissatisfaction.
Commonly used procedural methods for hair PNs include:
- Microdroplet technique—Injecting small quantities of polynucleotide hair treatment material into multiple, evenly spaced microdroplets across the treatment area for uniform distribution of the product.
- Linear retrograde technique—Injecting a continuous line of polynucleotide hair loss treatment material as the needle is withdrawn for targeted deposition along linear patterns of hair thinning.
- Fan technique—Radiating injections from a central point in a fan-like distribution, ideal for treating wider areas with fewer needle insertion points.
The PN-HPT™ consensus report described microdroplet and linear techniques using fine needles, including 30–32 gauge needles. This represents expert guidance for a specific product family rather than a validated standard for every PN or PDRN hair-loss treatment [2].
Benefits of Polynucleotides for Hair Treatment
Here are some benefits that polynucleotides for hair treatment bring to the table:
- May support scalp hydration and skin quality
- May influence inflammation- and oxidative-stress-related pathways
- Usually less invasive than surgical hair restoration
- May support the local follicular microenvironment
- May produce gradual changes in hair density or thickness
- Sessions may be completed in an outpatient setting
- Does not create surgical donor-site or recipient-site scars
- Common reactions are usually temporary, although risks remain
- Suitability depends on the diagnosis, age, health status, and product
What Are the Side Effects of Polynucleotide Injections?
Like other scalp-injection procedures, PN treatment may cause temporary local reactions. Reported or expected effects may include:
- Mild headache
- Occasional hematomas
- Temporary skin discoloration
- Local erythema, swelling, and tenderness
- Burning sensation for up to 12 hours after injections
- Mild, temporary pain during and after injections
To minimize side effects, use topical anesthetics like lidocaine to numb the skin before or after the injections. Also, advise your patients to:
- Apply calming creams or ice packs to the treated area [3]
- Stay out of direct sunlight and away from tanning beds for two days after the procedure
How Long Does Polynucleotide Treatment Last?
The duration and timing of PN-related hair changes have not been firmly established. In available studies, hair-density or thickness outcomes were assessed over approximately 12 to 24 weeks, but longer-term durability and maintenance requirements remain uncertain. Patients should not be promised visible regrowth within a specific time frame.
The Samadi et al. study evaluated a polynucleotide-based gel for pattern hair loss and reported patient and clinical assessments over follow-up. Before retaining the exact “ten sessions” and “85%” figures, verify them against the full text because the PubMed record does not provide an abstract. The study should be described as preliminary evidence rather than proof of long-term efficacy.
Can Polynucleotides Be Combined With Other Hair Loss Treatments?
Polynucleotides for hair restoration treatment may be combined with other hair-loss therapies in selected patients, but evidence that combination treatment improves efficacy is limited. A dermatologist should review potential interactions, timing, contraindications, and the strength of evidence for each treatment.
- Exosome or extracellular-vesicle products remain investigational for hair loss in many jurisdictions, and their composition and regulatory status vary.
- Glutathione injections, LED devices, and topical products may be offered as supportive options, but evidence for additive benefit with PN is insufficient.
- PN may also be used alongside topical minoxidil, appropriate oral medication, PRP, low-level light therapy, or microneedling, although combination protocols should be individualized.
It also pairs well with hair loss treatments like PRP, topical and oral medications, microneedling, and hair fillers for improved outcomes.
Conclusion
Book a meeting with the Medica Depot sales team to review product availability, purchasing requirements, and information relevant to your practice. Clinical use should follow applicable regulations, product instructions, and professional training.
Citations
[1] Ho, Chin H., et al. “Androgenetic Alopecia.” StatPearls – NCBI Bookshelf, 7 Jan. 2024, www.ncbi.nlm.nih.gov/books/NBK430924.
[2] Samadi, Aniseh, et al. “Efficacy and Tolerability Assessment of a Polynucleotide-based Gel for Improvement of Pattern Hair Loss.” Archives of Dermatological Research, vol. 316, no. 6, June 2024, p. 331. https://doi.org/10.1007/s00403-024-03088-9.
[3] Cavallini, Maurizio, et al. “Consensus Report on the Use of PN‐HPTTM (Polynucleotides Highly Purified Technology) in Aesthetic Medicine.” Journal of Cosmetic Dermatology, vol. 20, no. 3, Aug. 2020, pp. 922–28. https://doi.org/10.1111/jocd.13679.
This content was prepared and reviewed under our editorial guidelines , which govern how we source, verify, and update clinical and product information. Every claim is checked against peer-reviewed research, manufacturer documentation, or regulatory guidance before publication.
